Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02699190 · ClinicalTrials.gov registry record
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
A clinical trial, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- 236
- Enrollment target
NCT02699190 is a clinical trial that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 236 participants.
The verdict
NCT02699190 has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- 236 participants
- Enrollment target
Study Summary
Leukodystrophies, and other heritable disorders of the white matter of the brain, were previously resistant to genetic characterization, largely due to the extreme genetic heterogeneity of molecular causes. While recent work has demonstrated that whole genome sequencing (WGS), has the potential to dramatically increase diagnostic efficiency, significant questions remain around the impact on downstream clinical management approaches versus standard diagnostic approaches.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 236 participants |
| Start Date | 2017-01-06 |
| Est. Completion | 2024-10-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02699190
The ClinicalTrials.gov registry entry for NCT02699190 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 236 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02699190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02699190 about?
NCT02699190 is a clinical study titled "LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies". Leukodystrophies, and other heritable disorders of the white matter of the brain, were previously resistant to genetic characterization, largely due to the extreme genetic heterogeneity of molecular causes. While recent work has demonstrated that whole genome sequencing (WGS), has the potential to d...
What is the current status of trial NCT02699190?
This trial is currently completed. The enrollment target is 236 participants. The study started on 2017-01-06. Estimated completion is 2024-10-31.
Who is sponsoring clinical trial NCT02699190?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.